Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy.

ABSTRACT:

Importance

This observational study describes the efficacy and safety of rituximab in 5 patients with voltage-gated potassium channel (VGKC)-complex/leucine-rich, glioma-inactivated 1 (LGI1) antibody-associated encephalopathy. Rituximab is a monoclonal antibody that targets CD20 and is used to treat other neurologic and nonneurologic diseases.

Observations

This case series reports sequential seizure frequencies, modified Rankin Scale scores, and VGKC-complex antibody titers in 5 adult patients (median age, 65 years; range, 48-73 years) treated with rituximab. Median time from symptom onset to rituximab initiation was 414 days (range, 312-851 days). One patient showed a rapid clinical improvement after treatment with rituximab alone and experienced a rituximab-responsive clin

SUBMITTER: Irani SR 

PROVIDER: S-EPMC4477824 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature